 Organovo Holdings, Inc. Organovo Nasdaq: ONVO announced today that it has terminated the merger agreement with Tarveda Therapeutics, Inc. Tarveda, originally announced on December 16, 2019, and will continue to operate as an independent company. The Company had submitted the merger proposal and other related proposals to be voted upon at a Special Meeting of Stockholders, as described in its definitive proxy materials filed with the Securities and Exchange Commission on February 24, 2020. The Special Meeting of Stockholders was held on March 26, 2020 and adjourned until today. At todays reconvened special meeting, Organovos stockholders did not approve the merger related proposal and Organovo terminated the merger agreement in accordance with its terms. 